Edivoxetine
Edivoxetine (pronounced: ed-ih-vox-e-teen) is a norepinephrine reuptake inhibitor (NRI) that was under development by Eli Lilly for the adjunctive treatment of major depressive disorder (MDD) and attention-deficit hyperactivity disorder (ADHD). The development was discontinued in 2013.
Etymology
The term "Edivoxetine" is derived from the Latin roots "Edivo" meaning "to draw out" and "xetine" which is a common suffix used in the names of Selective serotonin reuptake inhibitors (SSRIs).
Pharmacology
Edivoxetine works by inhibiting the reuptake of norepinephrine, a neurotransmitter, thereby increasing the levels of norepinephrine in the brain. This mechanism of action is similar to that of other norepinephrine reuptake inhibitors.
Clinical Trials
Edivoxetine was tested in several clinical trials for its efficacy in treating major depressive disorder and attention-deficit hyperactivity disorder. However, the development of the drug was discontinued in 2013 due to unsatisfactory results.
Related Terms
- Norepinephrine
- Norepinephrine reuptake inhibitor
- Major depressive disorder
- Attention-deficit hyperactivity disorder
- Eli Lilly
See Also
External links
- Medical encyclopedia article on Edivoxetine
- Wikipedia's article - Edivoxetine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski